

Contents

List of Contributors XVII

Preface XXIII

A Personal Foreword XXV

Part One Principles 1

1 Virtual Screening of Chemical Space: From Generic Compound Collections to Tailored Screening Libraries 3

Markus Boehm

- 1.1 Introduction 3
- 1.2 Concepts of Chemical Space 4
- 1.3 Concepts of Druglikeness and Leadlikeness 6
- 1.4 Diversity-Based Libraries 8
 - 1.4.1 Concepts of Molecular Diversity 8
 - 1.4.2 Descriptor-Based Diversity Selection 9
 - 1.4.3 Scaffold-Based Diversity Selection 12
 - 1.4.4 Sources of Diversity 13
- 1.5 Focused Libraries 15
 - 1.5.1 Concepts of Focused Design 15
 - 1.5.2 Ligand-Based Focused Design 16
 - 1.5.3 Structure-Based Focused Design 17
- 1.5.4 Chemogenomics Approaches 18
- 1.6 Virtual Combinatorial Libraries and Fragment Spaces 20
- 1.7 Databases of Chemical and Biological Information 21
- 1.8 Conclusions and Outlook 24
- 1.9 Glossary 25
- References 26

Virtual Screening. Edited by C. Sotriffer
 Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
 ISBN: 978-3-527-32636-5

| | | |
|----------|--|-----------|
| 2 | Preparing and Filtering Compound Databases for Virtual and Experimental Screening | 35 |
| | <i>Maxwell D. Cummings, Éric Arnoult, Christophe Buyck, Gary Tresadern, Ann M. Vos, and Jörg K. Wegner</i> | |
| 2.1 | Introduction | 35 |
| 2.2 | Ligand Databases | 36 |
| 2.2.1 | Chemical Data Structures | 36 |
| 2.2.2 | 3D Conformations | 38 |
| 2.2.3 | Data Storage | 39 |
| 2.2.4 | Workflow Tools | 39 |
| 2.2.5 | Past Reviews and Recent Papers | 40 |
| 2.3 | Considering Physicochemical Properties | 42 |
| 2.3.1 | Druglikeness | 42 |
| 2.3.2 | Leadlikeness and Beyond | 43 |
| 2.4 | Undesirables | 43 |
| 2.4.1 | Screening Artifacts | 44 |
| 2.4.2 | Pharmacologically Promiscuous Compounds | 45 |
| 2.5 | Property-Based Filtering for Selected Targets | 46 |
| 2.5.1 | Antibacterials | 47 |
| 2.5.2 | CNS | 49 |
| 2.5.3 | Protein–Protein Interactions | 51 |
| 2.6 | Summary | 52 |
| | References | 53 |
| | | |
| 3 | Ligand-Based Virtual Screening | 61 |
| | <i>Herbert Koeppen, Jan Kriegl, Uta Lessel, Christofer S. Tautermann, and Bernd Wellenzohn</i> | |
| 3.1 | Introduction | 61 |
| 3.2 | Descriptors | 62 |
| 3.3 | Search Databases and Queries | 67 |
| 3.3.1 | Selection of Reference Ligands | 67 |
| 3.3.2 | Preparation of the Search Database | 68 |
| 3.4 | Virtual Screening Techniques | 68 |
| 3.4.1 | Similarity Searches | 69 |
| 3.4.1.1 | Similarity Measures | 69 |
| 3.4.1.2 | Practice of Similarity Searches | 69 |
| 3.4.1.3 | Selection of Descriptors | 71 |
| 3.4.1.4 | Data Fusion | 72 |
| 3.4.2 | Similarity Searches in Very Large Chemical Spaces | 72 |
| 3.4.3 | Machine Learning in Virtual Screening | 74 |
| 3.4.3.1 | Unsupervised Methods | 75 |
| 3.4.3.2 | Supervised Methods | 75 |
| 3.4.3.3 | Selected Techniques | 76 |
| 3.4.3.4 | Machine Learning Applications for Virtual Screening | 78 |
| 3.4.4 | Validation of Methods and Prediction of Success | 78 |

| | | |
|----------|---|------------|
| 3.5 | Conclusions | 79 |
| | References | 80 |
| 4 | The Basis for Target-Based Virtual Screening: Protein Structures | 87 |
| | <i>Jason C. Cole, Oliver Korb, Tjelvar S.G. Olsson, and John Liebeschuetz</i> | |
| 4.1 | Introduction | 87 |
| 4.2 | Selecting a Protein Structure for Virtual Screening | 87 |
| 4.2.1 | Why Are There Errors in Crystal Structures? | 87 |
| 4.2.2 | Possible Problems That May Occur in a Crystal Structure | 91 |
| 4.2.2.1 | Entirely Incorrect Models | 91 |
| 4.2.2.2 | Sequencing Errors | 91 |
| 4.2.2.3 | Misplaced Side Chains | 91 |
| 4.2.2.4 | Structural Disorder | 92 |
| 4.2.2.5 | Poorly Modeled Cofactors and Ligands | 92 |
| 4.2.2.6 | Erroneous Solvent | 94 |
| 4.2.3 | Structural Relevance | 95 |
| 4.2.3.1 | The Biologically Relevant Unit and Crystal Packing | 95 |
| 4.2.4 | Critical Evaluation of Models: Recognizing Issues in Structures | 98 |
| 4.3 | Setting Up a Protein Model for vHTS | 101 |
| 4.3.1 | Binding Site Definition | 101 |
| 4.3.2 | Protonation | 104 |
| 4.3.3 | Treatment of Solvent in Docking | 104 |
| 4.3.4 | Use of Protein-Based Constraints in Docking | 105 |
| 4.3.5 | Protein Flexibility | 106 |
| 4.3.5.1 | Pose Prediction | 107 |
| 4.3.5.2 | Virtual Screening | 108 |
| 4.4 | Summary | 109 |
| 4.5 | Glossary of Crystallographic Terms | 110 |
| 4.5.1 | R-Factor | 110 |
| 4.5.2 | Resolution | 110 |
| 4.5.3 | 2mFo-DFc Map | 110 |
| | References | 110 |
| 5 | Pharmacophore Models for Virtual Screening | 115 |
| | <i>Patrick Markt, Daniela Schuster, and Thierry Langer</i> | |
| 5.1 | Introduction | 115 |
| 5.2 | Compilation of Compounds | 116 |
| 5.2.1 | Chemical Structure Generation | 116 |
| 5.2.2 | Conformational Analysis | 116 |
| 5.3 | Pharmacophore Model Generation | 117 |
| 5.3.1 | State of the Art | 117 |
| 5.3.2 | Structure-Based Methods | 117 |
| 5.3.3 | Ligand-Based Methods | 118 |
| 5.3.4 | Limitations of Ligand-Based Methods | 119 |
| 5.4 | Validation of Pharmacophore Models | 119 |

| | | |
|----------|--|------------|
| 5.4.1 | Chemical Databases for Validation | 119 |
| 5.4.2 | Enrichment Assessment | 121 |
| 5.4.3 | Enrichment Metrics | 122 |
| 5.4.4 | Receiver Operating Characteristic Curve Analysis | 124 |
| 5.4.5 | Area Under the ROC Curve | 125 |
| 5.5 | Pharmacophore-Based Screening | 127 |
| 5.5.1 | DS CATALYST | 128 |
| 5.5.2 | UNITY (GALAHAD/GASP) | 128 |
| 5.5.3 | LIGANDSCOUT | 129 |
| 5.5.4 | MOE | 130 |
| 5.5.5 | PHASE | 130 |
| 5.6 | Postprocessing of Pharmacophore-Based Screening Hits | 131 |
| 5.6.1 | Lead- and Druglikeness | 131 |
| 5.6.2 | Structural Similarity Analysis | 131 |
| 5.7 | Pharmacophore-Based Parallel Screening | 132 |
| 5.8 | Application Examples for Synthetic Compound Screening | 133 |
| 5.8.1 | 17 β -Hydroxysteroid Dehydrogenase 1 Inhibitors | 133 |
| 5.8.2 | Cannabinoid Receptor 2 (CB ₂) Ligands | 134 |
| 5.8.3 | Further Application Examples | 136 |
| 5.9 | Application Examples for Natural Product Screening | 136 |
| 5.9.1 | Cyclooxygenase (COX) Inhibitors | 139 |
| 5.9.2 | Sigma-1 (σ_1) Receptor Ligands | 139 |
| 5.9.3 | Acetylcholinesterase Inhibitors | 140 |
| 5.9.4 | Human Rhinovirus Coat Protein Inhibitors | 141 |
| 5.9.5 | Quorum-Sensing Inhibitors | 141 |
| 5.9.6 | Peroxisome Proliferator-Activated Receptor γ Ligands | 141 |
| 5.9.7 | β -Ketoacyl-Acyl Carrier Protein Synthase III Inhibitors | 142 |
| 5.9.8 | 5-Lipoxygenase Inhibitors | 142 |
| 5.9.9 | 11 β -Hydroxysteroid Dehydrogenase Type 1 Inhibitors | 142 |
| 5.9.10 | Pharmacophore-Based Parallel Screening of Natural Products | 143 |
| 5.10 | Conclusions | 143 |
| | References | 144 |
| 6 | Docking Methods for Virtual Screening: Principles and Recent Advances | 153 |
| | <i>Didier Rognan</i> | |
| 6.1 | Principles of Molecular Docking | 153 |
| 6.1.1 | Sampling Degrees of Freedom of the Ligand | 154 |
| 6.1.1.1 | Generation of Multiconformer Ligand Libraries | 154 |
| 6.1.1.2 | Incremental Construction | 154 |
| 6.1.1.3 | Stochastic Methods | 155 |
| 6.1.2 | Scoring Ligand Poses | 156 |
| 6.1.2.1 | Empirical Scoring Functions | 156 |
| 6.1.2.2 | Knowledge-Based Potential of Mean Force | 156 |

| | | |
|---------|---|-----|
| 6.1.2.3 | Force Fields | 157 |
| 6.1.2.4 | Critical Evaluation of Scoring Functions | 157 |
| 6.2 | Docking-Based Virtual Screening Flowchart | 158 |
| 6.2.1 | Ligand Setup | 158 |
| 6.2.2 | Protein Setup | 159 |
| 6.2.3 | Docking | 160 |
| 6.2.4 | Postdocking Analysis | 161 |
| 6.3 | Recent Advances in Docking-Based VS Methods | 162 |
| 6.3.1 | Novel Docking Algorithms | 162 |
| 6.3.2 | Fragment Docking | 164 |
| 6.3.3 | Postdocking Refinement | 164 |
| 6.3.3.1 | Rescoring with Rigorous Scoring Functions | 164 |
| 6.3.3.2 | Topological Scoring by Protein–Ligand Interaction Fingerprint (IFP) | 165 |
| 6.3.4 | Addressing Protein Flexibility | 166 |
| 6.3.5 | Solvated or Dry? | 168 |
| 6.4 | Future Trends in Docking | 168 |
| | References | 169 |

Part Two Challenges 177

| | | |
|----------|--|------------|
| 7 | The Challenge of Affinity Prediction: Scoring Functions for Structure-Based Virtual Screening | 179 |
| | <i>Christoph Sotriffer and Hans Matter</i> | |
| 7.1 | Introduction | 179 |
| 7.2 | Physicochemical Basis of Protein–Ligand Recognition | 180 |
| 7.3 | Classes of Scoring Functions | 185 |
| 7.3.1 | Force Field-Based Methods | 185 |
| 7.3.2 | Empirical Scoring Functions | 189 |
| 7.3.3 | Knowledge-Based Scoring Functions | 191 |
| 7.4 | Interesting New Approaches to Scoring Functions | 192 |
| 7.4.1 | Improved Treatment of Hydrophobicity and Dehydration | 192 |
| 7.4.2 | Development and Validation of SFCscore | 194 |
| 7.4.3 | Consensus Scoring | 195 |
| 7.4.4 | Tailored Scoring Functions | 196 |
| 7.4.5 | Structural Interaction Fingerprints | 199 |
| 7.5 | Comparative Assessment of Scoring Functions | 200 |
| 7.6 | Tailoring Scoring Strategies in Virtual Screening | 203 |
| 7.6.1 | Toward a Strategy for Applying Scoring Functions | 203 |
| 7.6.2 | Retrospective Validation Prior to Prospective Virtual Screening | 204 |
| 7.6.3 | Lessons Learned: Improvements in Scoring Evaluations | 205 |
| 7.6.4 | Postfiltering Results of Virtual Screenings | 205 |
| 7.7 | Caveats for Development of Scoring Functions | 206 |
| 7.7.1 | General Points | 206 |
| 7.7.2 | Biological Data | 207 |

| | | |
|----------|---|------------|
| 7.7.3 | Structural Data on Protein–Ligand Complexes and Decoy Data Sets | 207 |
| 7.7.4 | Cooperativity and Other Model Deficiencies | 208 |
| 7.8 | Conclusions | 209 |
| | References | 210 |
| 8 | Protein Flexibility in Structure-Based Virtual Screening: From Models to Algorithms | 223 |
| | <i>Angela M. Henzler and Matthias Rarey</i> | |
| 8.1 | How Flexible Are Proteins? – A Historical Perspective | 223 |
| 8.1.1 | Ligand Binding Is Coupled with Protein Conformational Change | 223 |
| 8.1.2 | Types of Flexibility | 224 |
| 8.2 | Flexible Protein Handling in Protein–Ligand Docking | 225 |
| 8.2.1 | Docking Following Conformational Selection | 227 |
| 8.2.1.1 | Protein Flexibility Analysis and Protein Ensemble Generation | 227 |
| 8.2.1.2 | Ensemble-Based Docking Techniques | 228 |
| 8.2.2 | Induced Fit Docking: Single-Structure-Based Docking Techniques | 231 |
| 8.2.2.1 | Consecutive Ligand and Protein Conformational Change | 232 |
| 8.2.2.2 | Simultaneous Ligand and Protein Conformational Change | 234 |
| 8.2.3 | Integrated Docking Approaches | 235 |
| 8.3 | Flexible Protein Handling in Docking-Based Virtual Screening | 236 |
| 8.3.1 | Efficiency of Fully Flexible Docking Approaches in Retrospective | 237 |
| 8.3.2 | Discrimination of Binders and Nonbinders | 238 |
| 8.4 | Summary | 238 |
| | References | 239 |
| 9 | Handling Protein Flexibility in Docking and High-Throughput Docking: From Algorithms to Applications | 245 |
| | <i>Claudio N. Cavasotto</i> | |
| 9.1 | Introduction: Docking and High-Throughput Docking in Drug Discovery | 245 |
| 9.2 | The Challenge of Accounting for Protein Flexibility in Docking | 246 |
| 9.2.1 | Theoretical Understanding of the Problem | 246 |
| 9.2.2 | Docking Failures Due to Protein Flexibility | 247 |
| 9.3 | Accounting for Protein Flexibility in Docking-Based Drug Discovery and Design | 250 |
| 9.3.1 | Receptor Ensemble-Based Docking Methods | 252 |
| 9.3.2 | Single-Structure-Based Docking Methods | 253 |
| 9.3.3 | Multilevel Methods | 256 |
| 9.3.4 | Homology Modeling | 257 |
| 9.4 | Conclusions | 257 |
| | References | 258 |

| | | |
|-----------|--|------------|
| 10 | Consideration of Water and Solvation Effects in Virtual Screening | 263 |
| | <i>Johannes Kirchmair, Gudrun M. Spitzer, and Klaus R. Liedl</i> | |
| 10.1 | Introduction | 263 |
| 10.2 | Experimental Approaches for Analyzing Water Molecules | 266 |
| 10.3 | Computational Approaches for Analyzing Water Molecules | 271 |
| 10.3.1 | Molecular Dynamics Simulations | 271 |
| 10.3.2 | Empirical and Implicit Considerations of Solvation Effects | 274 |
| 10.4 | Water-Sensitive Virtual Screening: Approaches and Applications | 275 |
| 10.4.1 | Protein–Ligand Docking | 275 |
| 10.4.2 | Pharmacophore Modeling | 278 |
| 10.5 | Conclusions and Recommendations | 281 |
| | References | 282 |

Part Three Applications and Practical Guidelines 291

| | | |
|-----------|--|------------|
| 11 | Applied Virtual Screening: Strategies, Recommendations, and Caveats | 293 |
| | <i>Dagmar Stumpfe and Jürgen Bajorath</i> | |
| 11.1 | Introduction | 293 |
| 11.2 | What Is Virtual Screening? | 293 |
| 11.3 | Spectrum of Virtual Screening Approaches | 294 |
| 11.4 | Molecular Similarity as a Foundation and Caveat of Virtual Screening | 295 |
| 11.5 | Goals of Virtual Screening | 296 |
| 11.6 | Applicability Domain | 297 |
| 11.7 | Reference and Database Compounds | 299 |
| 11.8 | Biological Activity versus Compound Potency | 300 |
| 11.9 | Methodological Complexity and Compound Class Dependence | 301 |
| 11.10 | Search Strategies and Compound Selection | 302 |
| 11.11 | Virtual and High-Throughput Screening | 304 |
| 11.12 | Practical Applications: An Overview | 306 |
| 11.13 | LFA-1 Antagonist | 307 |
| 11.13.1 | Similarity Searching | 308 |
| 11.13.2 | Results and Further Calculations | 309 |
| 11.14 | Selectivity Searching | 310 |
| 11.14.1 | Selectivity Searching for Cathepsin K-Selective Inhibitors | 311 |
| 11.14.2 | Selectivity Searching with 2D Fingerprints | 312 |
| 11.14.3 | Identification of Selective Inhibitors | 313 |
| 11.15 | Concluding Remarks | 314 |
| | References | 315 |
| 12 | Applications and Success Stories in Virtual Screening | 319 |
| | <i>Hans Matter and Christoph Sotriffer</i> | |
| 12.1 | Introduction | 319 |
| 12.2 | Practical Considerations | 320 |

| | | |
|----------|--|-----|
| 12.3 | Successful Applications of Virtual Screening | 321 |
| 12.3.1 | Structure-Based Virtual Screening | 322 |
| 12.3.1.1 | Kinases | 322 |
| 12.3.1.2 | Proteases | 324 |
| 12.3.1.3 | Nuclear Receptors | 325 |
| 12.3.1.4 | Short-Chain Dehydrogenases | 327 |
| 12.3.1.5 | G Protein-Coupled Receptors (GPCRs) | 327 |
| 12.3.1.6 | Antiinfectives | 331 |
| 12.3.1.7 | Other Target Proteins | 333 |
| 12.3.2 | Structure-Based Library Design | 336 |
| 12.3.3 | Ligand-Based Virtual Screening | 338 |
| 12.3.3.1 | Ion Channels | 339 |
| 12.3.3.2 | Kinases | 340 |
| 12.3.3.3 | Nuclear Hormone Receptors | 341 |
| 12.3.3.4 | G Protein-Coupled Receptors (GPCRs) | 342 |
| 12.3.3.5 | Other Protein Targets | 345 |
| 12.4 | Conclusion | 347 |
| | References | 348 |

Part Four Scenarios and Case Studies: Routes to Success 359

| | | |
|-----------|--|------------|
| 13 | Scenarios and Case Studies: Examples for Ligand-Based Virtual Screening | 361 |
| | <i>Trevor Howe, Daniele Bemporad, and Gary Tresadern</i> | |
| 13.1 | Introduction | 361 |
| 13.2 | 1D Ligand-Based Virtual Screening | 362 |
| 13.3 | 2D Ligand-Based Virtual Screening | 363 |
| 13.3.1 | Examples from the Literature | 363 |
| 13.3.2 | Applications at J&JPRD Europe | 366 |
| 13.4 | 3D Ligand-Based Virtual Screening | 368 |
| 13.4.1 | Methods | 370 |
| 13.4.2 | 3DLBVS Examples | 372 |
| 13.4.2.1 | CRF1 Antagonists | 372 |
| 13.4.2.2 | Ion Channel Antagonism | 375 |
| 13.4.2.3 | Metabotropic Glutamate Receptor | 375 |
| 13.5 | Summary | 376 |
| | References | 377 |
| 14 | Virtual Screening on Homology Models | 381 |
| | <i>Róbert Kiss and György M. Keserü</i> | |
| 14.1 | Introduction | 381 |
| 14.2 | Homology Models versus Crystal Structures: Comparative Evaluation of Screening Performance | 382 |
| 14.2.1 | Soluble Proteins | 382 |
| 14.2.2 | Membrane Proteins | 392 |

| | | |
|-----------|---|------------|
| 14.3 | Challenges of Homology Model-Based Virtual Screening | 394 |
| 14.3.1 | Level of Sequence Identity | 395 |
| 14.3.2 | Main-Chain Flexibility | 396 |
| 14.3.3 | Side-Chain Conformation: Induced Fit Effects of Ligands | 396 |
| 14.3.4 | Loop Modeling | 397 |
| 14.4 | Case Studies | 399 |
| 14.4.1 | Virtual Screening on the Homology Model of Histamine H4 Receptor | 399 |
| 14.4.2 | Virtual Screening on the Homology Model of Janus Kinase 2 | 402 |
| | References | 404 |
| 15 | Target-Based Virtual Screening on Small-Molecule Protein Binding Sites | 411 |
| | <i>Ralf Heinke, Urszula Uciechowska, Manfred Jung, and Wolfgang Sippl</i> | |
| 15.1 | Introduction | 411 |
| 15.1.1 | Pharmacophore-Based Methods | 412 |
| 15.1.2 | Ligand Docking | 412 |
| 15.1.3 | Virtual Screening | 413 |
| 15.1.4 | Binding Free Energy Calculations | 414 |
| 15.2 | Structure-Based VS for Histone Arginine Methyltransferase PRMT1 Inhibitors | 414 |
| 15.2.1 | Structure-Based VS of the NCI Diversity Set | 415 |
| 15.2.2 | Pharmacophore-Based VS | 417 |
| 15.3 | Identification of Nanomolar Histamine H ₃ Receptor Antagonists by Structure- and Pharmacophore-Based VS | 422 |
| 15.3.1 | Generation of Homology Model of the hH ₃ R and hH ₃ R Antagonist Complexes | 423 |
| 15.3.2 | Validation of the Homology Model by Docking Known Antagonists into the hH ₃ R Binding Site | 424 |
| 15.3.3 | Pharmacophore-Based VS | 425 |
| 15.3.4 | Experimental Testing of the Identified Hits | 429 |
| 15.3.5 | Discussion of the Applied VS Strategies | 429 |
| 15.4 | Summary | 431 |
| | References | 432 |
| 16 | Target-Based Virtual Screening to Address Protein–Protein Interfaces | 435 |
| | <i>Olivier Sperandio, Maria A. Miteva, and Bruno O. Villoutreix</i> | |
| 16.1 | Introduction | 435 |
| 16.2 | Some Recent PPIM Success Stories | 437 |
| 16.3 | Protein–Protein Interfaces | 438 |
| 16.3.1 | Interface Pockets, Flexibility, and Hot Spots | 440 |
| 16.3.2 | Databases and Tools to Analyze Interfaces | 442 |
| 16.4 | PPIMs' Chemical Space and ADME/Tox Properties | 442 |

| | | |
|-----------|--|------------|
| 16.5 | Drug Discovery, Chemical Biology, and <i>In Silico</i> Screening Methods: Overview and Suggestions for PPIM Search | 447 |
| 16.6 | Case Studies | 450 |
| 16.6.1 | PPI Stabilizers: Superoxide Dismutase Type 1 | 450 |
| 16.6.2 | PPI Inhibitors: Lck | 452 |
| 16.6.3 | Allosteric Inhibitors: Antitrypsin Polymerization | 455 |
| 16.7 | Conclusions and Future Directions | 457 |
| | References | 458 |
| 17 | Fragment-Based Approaches in Virtual Screening | 467 |
| | <i>Danzhi Huang and Amedeo Caflisch</i> | |
| 17.1 | Introduction | 467 |
| 17.2 | <i>In Silico</i> Fragment-Based Approaches | 468 |
| 17.3 | Our Approach to High-Throughput Fragment-Based Docking | 470 |
| 17.3.1 | Decomposition of Compounds into Fragments | 471 |
| 17.3.2 | Docking of Anchor Fragments | 471 |
| 17.3.3 | Flexible Docking of Library Compounds | 472 |
| 17.3.4 | LIECE Binding Energy Evaluation | 472 |
| 17.3.5 | Consensus Scoring | 475 |
| 17.3.6 | <i>In Silico</i> Screening Campaigns | 475 |
| 17.3.7 | West Nile Virus NS3 Protease (Flaviviral Infections) | 475 |
| 17.3.8 | EphB4 Tyrosine Kinase (Cancer) | 477 |
| 17.4 | Lessons Learned from Our Fragment-Based Docking | 479 |
| 17.5 | Challenges of Fragment-Based Approaches | 481 |
| | References | 482 |
| | Appendix A: Software Overview | 491 |
| | Appendix B: Virtual Screening Application Studies | 501 |
| | Index | 511 |